Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459150 | 0.75 | SIRT2 (0.57) | SIRT2TARBP2HTTKDM4ETP53 | |
| SCHEMBL3454990 | 0.72 | RAB9A (0.47) | TARBP2HTTKDM4ETP53SMN1; SMN2 | |
| SCHEMBL29764175 | 0.72 | BRD4 (0.47) | TARBP2HTTKDM4ETP53HSD17B10 | |
| SCHEMBL21831480 | 0.72 | BRD4 (0.47) | TARBP2HTTKDM4ETP53HSD17B10 | |
| SCHEMBL30101740 | 0.70 | BRD4 (0.47) | HTTKDM4EHSD17B10MAPTCYP1A2 | |
| SCHEMBL5919012 | 0.69 | THRB (0.63) | HTTKDM4ETP53SMN1; SMN2MAPT | |
| SCHEMBL25389928 | 0.69 | BRD4 (0.49) | HTTKDM4EHSD17B10MAPTMEN1 | |
| SCHEMBL31288369 | 0.69 | BRD4 (0.49) | HTTKDM4EHSD17B10MAPTMEN1 | |
| SCHEMBL7990062 | 0.69 | SIRT2 (0.53) | SIRT2TARBP2HTTKDM4ETP53 | |
| SCHEMBL22224841 | 0.69 | HSD17B10 (0.52) | HTTKDM4ESMN1; SMN2HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2240016-A1 | AMPK MODULATORS | Mercury Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | PRKAG1, PRKAG2, PRKAG3 | SIRT2 164/4885TARBP2 4319/4885HTT 4396/4885 |
| US-20120302576-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | SIRT2 164/4885TARBP2 4319/4885HTT 4396/4885 |
| US-20100009992-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | SIRT2 164/4885TARBP2 4319/4885HTT 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.